Tirzepatide Dosage: How the Label Steps It Up

Why does the Tirzepatide dose start low?

The makers of Tirzepatide built it to remain in the body for days. This made a once-a-week shot possible. They also learned that raising the dose slowly can ease nausea.

The labeled start is 2.5 mg once a week. After four weeks, it may rise by 2.5 mg if side effects allow. The weekly long-term doses your prescriber may consider are 5, 10, or 15 mg. The highest approved and studied dose is 15 mg.

The shot goes under the skin on the same day each week. Tirzepatide attaches to albumin, a blood protein. After 5 days, your body has cleared about half, leaving some until the next shot.

This page gives the FDA label steps and the study plans. The schedule can’t serve as your personal dose plan. A licensed prescriber decides what fits your health and response.

Tirzepatide dosage: what steps are on the FDA label?

Here are the slow steps used in phase 3 studies, the final large tests before approval ^[6]:

• Weeks 1–4: 2.5 mg once a week, which is the starting dose, not a long-term dose.
• Weeks 5–8: 5 mg once a week.
• Weeks 9–12: 7.5 mg once a week.
• Weeks 13–16: 10 mg once a week.
• Weeks 17–20: 12.5 mg once a week.
• Week 21 onward: 15 mg weekly. That is the highest dose.

The phase 3 trials studied long-term doses of 5, 10, and 15 mg. People reached those goals during the 20-week rise. A prescriber may slow the rise when side effects are hard to bear ^[6].

The same steps apply to long-term weight care. For type 2 diabetes, the approved long-term range is 5–15 mg once a week after the 2.5 mg start. The sleep apnea studies used 10 or 15 mg as long-term doses ^[11][12].

SURPASS compared Tirzepatide with semaglutide 1 mg. The Tirzepatide groups used 5/10/15 mg, meaning five, ten, or fifteen milligrams ^[3]. In Chinese adults with early type 2 diabetes, the same 5/10/15 mg groups had sugar-test changes of −2.04/−1.93/−2.02% at 40 weeks, in the same order ^[27].

Tirzepatide injection: where does the shot go?

The Tirzepatide shot enters the soft layer just beneath your skin. It doesn’t go into a vein or deep into muscle. Studies used three body spots: belly, upper arm, and thigh ^[1][4][5].

The label tells you to change the spot from one shot to the next. That can help limit redness, itching, soreness, bruising, or a small lump. These skin problems appear in trial and later safety reports ^[8][22].

The prescription drug comes as a liquid in a pre-filled pen. The marketed pen must stay cold. Mixing and storage can differ by the exact product, so the main trial papers don’t give one set of rules ^[1].

Some related medicines come as pills. Approved Tirzepatide does not. Approval covers only the shot placed beneath your skin.

Tirzepatide dose: why does one shot last a week?

Tirzepatide has a roughly 5-day half-life. Half-life tells how long your body takes to clear half a dose. A small fatty part helps the medicine stay in your blood.

That fatty part attaches to albumin, a blood protein. Albumin slows the drug from leaving too fast. After 5 days, about half the dose remains ^[1].

A 2020 study found that Tirzepatide slowed stomach emptying at first. The effect was much like other long-acting GLP-1 drugs, which copy one gut hormone. Stomach slowing with GLP-1 drugs then grew weaker with continued use ^[15].

The 5-day half-life means some drug remains after the last shot. This matters when a prescriber thinks about surgery or pregnancy. A chart alone can’t settle that choice.

Older adults with type 2 diabetes were also studied. Low blood sugar rates hardly changed whether people used insulin or another pill that raises insulin. This suggests the blood sugar effect stayed similar across age groups ^[19].

Tirzepatide reviews: how often did side effects stop treatment?

Several reviews show how often side effects led people to stop Tirzepatide.

Stomach, pancreas, and gallbladder: A 2023 review combined nine trials. It couldn’t show more pancreatitis, which means a swollen pancreas. Gallbladder or bile-duct trouble did happen more often. The paper gave one 95% range for pancreas risk and another 95% range for gallbladder trouble. These ranges show you how much an estimate could vary ^[7].

A second review combined 13 obesity trials in people without diabetes. Compared with placebo, the Tirzepatide groups had more stomach and bowel problems. The paper gave a 95% range, showing how much that estimate could vary ^[13]. A 2026 paper also examined reports sent to a drug safety system after use. Those reports named nausea, vomiting, diarrhoea, constipation, and egg-smelling burps ^[2]. They can flag problems but can’t show the true rate caused by the drug.

Tirzepatide against dulaglutide: A 2026 review found larger changes in sugar and weight with Tirzepatide. Side effects led about 32% more people to stop Tirzepatide. The stronger results came with harder side effects ^[26].

Reports outside trials: A 2025 review used safety reports sent from 2022–2025. Giving the wrong dose was the most common report ^[22]. Such reports can warn of a problem, but they don’t give a dependable rate.

Your price can vary with the approved use, insurance, and savings offers. This site doesn’t track current prices. If you have insurance, the number on your card can connect you with the company that manages drug coverage. The drug maker can also give current cost details.